Distribuzione geografica
Continente #
NA - Nord America 7991
EU - Europa 2900
AS - Asia 639
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 6
AF - Africa 3
OC - Oceania 3
Totale 11557
Nazione #
US - Stati Uniti d'America 7816
DE - Germania 716
SE - Svezia 616
UA - Ucraina 530
CN - Cina 521
IT - Italia 387
CA - Canada 172
GB - Regno Unito 164
IE - Irlanda 118
FI - Finlandia 105
FR - Francia 56
BE - Belgio 53
RU - Federazione Russa 43
IN - India 37
DK - Danimarca 34
NL - Olanda 28
VN - Vietnam 28
AT - Austria 25
TR - Turchia 20
JP - Giappone 19
EU - Europa 14
RO - Romania 6
BG - Bulgaria 4
BR - Brasile 4
IR - Iran 4
ID - Indonesia 3
KR - Corea 3
PL - Polonia 3
AU - Australia 2
ES - Italia 2
HU - Ungheria 2
MX - Messico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CU - Cuba 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
SG - Singapore 1
SR - Suriname 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 11557
Città #
Ann Arbor 1839
Woodbridge 1037
Houston 740
Fairfield 647
Jacksonville 588
Chandler 457
Frankfurt am Main 403
Wilmington 367
Dearborn 323
Ashburn 277
Seattle 236
Princeton 224
Cambridge 207
Milan 132
Nanjing 125
Dublin 118
Lawrence 103
Lachine 102
Altamura 100
Beijing 92
Brussels 53
Göttingen 52
Nanchang 42
Andover 37
Philadelphia 34
Shenyang 32
Changsha 31
San Diego 31
Toronto 31
Guangzhou 29
Hebei 28
Ottawa 28
Vienna 24
Huizen 22
Boardman 21
Fürstenwalde 18
Fremont 17
Jiaxing 17
Lissone 16
Norwalk 16
Redmond 16
Nürnberg 15
University Park 15
Jinan 14
Tianjin 14
Chicago 13
Hangzhou 13
Hefei 13
Kunming 13
Mountain View 13
London 11
Zhengzhou 10
Falls Church 9
Auburn Hills 8
Dong Ket 8
Edmonton 8
Los Angeles 8
Rome 8
Shanghai 7
Bologna 6
San Mateo 6
Leawood 5
Mumbai 5
Taizhou 5
Gorgonzola 4
Haikou 4
Kiev 4
Kocaeli 4
Plovdiv 4
Simi Valley 4
Chongqing 3
Desio 3
Detroit 3
Helsinki 3
Islington 3
Jakarta 3
Monmouth Junction 3
Montréal 3
Ningbo 3
Sacramento 3
Taiyuan 3
Bolzano 2
Buffalo 2
Caserta 2
Chengdu 2
Como 2
Daejeon 2
Fiumicino 2
Groningen 2
Hesperia 2
Lanzhou 2
Laurel 2
Lynnwood 2
Munich 2
New York 2
Osaka 2
Padova 2
Verona 2
Absecon 1
Adliswil 1
Totale 9032
Nome #
Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease 373
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia 356
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 294
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 266
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 258
Imatinib long term effects study: three years of follow-up and assessment 227
A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation 219
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 218
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 187
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 175
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 174
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 171
A prospective study on cardiovascular events after acute pulmonary embolism 164
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 160
Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report 155
Thrombosis of the splenoportal axis after splenectomy 151
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 146
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 145
Severe, reversible nelarabine-induced neuropathy and myelopathy 142
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone 136
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report 135
Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma 134
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 131
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study 129
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 128
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 127
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance 123
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 122
Crizotinib in anaplastic large-cell lymphoma 122
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 122
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy 122
Recurrent preeclapsia: The role of acquired and heritable thrombophilia 120
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 117
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) 117
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 117
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 115
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 115
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 115
Combined prophylactic low-molecular weight heparin and low dose aspirin reduces the occurrences of adverse pregnancy outcome in multiparous women with preeclampsia and intrauterine fetal growth restriction in antecedent pregnancy 114
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease 113
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 112
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 111
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 110
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study 109
Platelet activation during plasma-reduced multicomponent PLT collection: A comparison between COBE Trima and Spectra LRS turbo cell separators 108
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials 108
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 107
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination 107
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 102
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 102
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease 99
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared? 97
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 96
A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript 95
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group 94
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment 90
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 90
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia 89
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies 89
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies 88
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 87
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 87
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 87
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) 86
Reviewed diagnosis of primary and secondary immune thrombocytopenic purpura in 79 adult patients hospitalized in 2000-2002 85
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 83
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 82
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program 81
Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy 78
Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds 78
Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions 78
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 77
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 76
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 76
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature 70
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 68
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 65
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients 65
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD 65
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 64
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system 63
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 63
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 63
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [2] 62
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 61
Imatinib concentrations in human milk 60
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate 59
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 59
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 59
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments 58
Mast cell leukemia: A report of ten cases 58
Advanced mast cell disease: an Italian Hematological Multicenter experience 58
The effect of prior exposure to imatinib on transplant-related mortality 53
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study 50
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study 49
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells 47
Totale 11463
Categoria #
all - tutte 22761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22761

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20185 0000 00 00 0005
2018/2019960 1518168 29131 4228 71118253231
2019/20202888 363224207185 250308 463219 29413619742
2020/20211660 13484238214 107108 168100 1761806685
2021/20221088 505890111 85103 4285 7192106195
2022/20232129 293671195163 127311 3892 12226910
Totale 11879